Table 1. Prevalence of KRAS-variant in a control population and in patients with types 1 and 2 endometrial cancer.

KRAS-variant	Control	Type 1 cancer	Type 2 cancer
Non-variant homozygotes	501 (86.1%)	360 (83.3%)	28 (75.7%)
Mutant/heterozygotes	81 (13.9%)	70 (16.7%)	9 (24.3%)
p-value	0.19